Optimal Treatment Sequencing in mCRPC Improves Survival
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
ASCO GU 2017 Data Analysis
- March 14, 2017
Big data analysis from six European countries (44 medical centers, August 2012-July 2016) demonstrates that sequential chemotherapy and hormonal therapy ordering significantly impacts overall survival in mCRPC.
Optimal Treatment Sequence
Docetaxel → Cabazitaxel → Novel ART Agents (abiraterone, enzalutamide alternatives)
Key Efficacy Outcomes by Sequencing
Overall Survival from Docetaxel Initiation:
- Docetaxel → Cabazitaxel: 30.1 months
- Docetaxel → ART → Cabazitaxel: 37.1 months
- Docetaxel → Cabazitaxel → ART: 40.1 months
PSA Response (≥50% decline):
- Group 1: 35.6%
- Group 2: 44.6%
- Group 3: 46.7%
Clinical Characteristics
Median age: 67 years; ECOG 0-1: 89.3%; Pain present: 45.1%; Visceral metastasis: 10.8%
Clinical Significance
Earlier introduction of novel androgen receptor-targeted agents after docetaxel may optimize overall survival in mCRPC compared to sequential use of both chemotherapy agents.
Data Source
ASCO GU 2017; Data: http://meetinglibrary.asco.org/content/178765-197
Informational only; treatment decisions should involve oncology consultation.
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1